Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002222041 | SCV002499537 | uncertain significance | Monogenic diabetes | 2022-04-13 | reviewed by expert panel | curation | The c.749A>C variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of glutamine to proline at codon 250 (p.Gln250Pro) of NM_000545.8. This variant is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). This variant is also absent from gnomAD v2.1.1 (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.716, which is greater than the MDEP VCEP threshold of 0.70 (PP3). In summary, c.749A>C meets the criteria to be classified as a variant of uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PM1_Supporting, PM2_Supporting, PP3. |
Athena Diagnostics | RCV000518130 | SCV000613626 | uncertain significance | not specified | 2016-10-27 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV002463713 | SCV002605019 | likely risk allele | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. However, more evidence is required to confer the association of this particular variant rs1555211982 with MODY3. |